There has been a good deal of movement on the EU biosimilars front this month. The European Commission has granted marketing authorization to two more biosimilar medicines, bringing the number of EU-approved biosimilars so far to 43, containing a total of 14 different substances. And a further four biosimilars are up for an opinion this week from the European Medicines Agency’s drug evaluation committee, the CHMP, which is currently holding its monthly meeting.
One of the two biosimilars authorized by the commission is Sandoz International GMBH’s Zessly (infliximab), a version of Janssen Pharmaceutical Cos.’s Remicade
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?